Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours
Research output: Contribution to journal › Article
Colleges, School and Institutes
- Glioma Team, Division of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
- Molecular Diagnostics Department, The Institute of Cancer Research and Clinical Genomics, The Royal Marsden NHS Foundation, London, United Kingdom.
- Paediatric Drug Development Team, Children and Young People's Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
- Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
- The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia.
- UQ Child Health Research Centre, The University of Queensland, Brisbane, Australia.
- Newcastle University
- Developmental Biology and Cancer Programme, UCL GOS Institute of Child Health, London, United Kingdom.
- Haematology, Cellular and Molecular Diagnostics Service, UCL GOS Institute of Child Health, London, United Kingdom.
- Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
- Haemato-Oncology Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
- HNJ-CNIO Clinical Research Unit and Hospital Universitario Niño Jesus, Madrid, Spain.
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
- Centre for Cancer Research and Cell Biology, Queen's University Belfast, BT9 7AB, Northern Ireland, United Kingdom.
The implementation of personalised medicine in childhood cancers has been limited by a lack of clinically validated multi-target sequencing approaches specific for paediatric solid tumours. In order to support innovative clinical trials in high-risk patients with unmet need, we have developed a clinically relevant targeted sequencing panel spanning 311 kb and comprising 78 genes involved in childhood cancers. A total of 132 samples were used for the validation of the panel, including Horizon Discovery cell blends (n=4), cell lines (n=15), formalin-fixed paraffin embedded (FFPE, n=83) and fresh frozen tissue (FF, n=30) patient samples. Cell blends containing known single nucleotide variants (SNVs, n=528) and small insertion-deletions (indels n=108) were used to define panel sensitivities of ≥98% for SNVs and ≥83% for indels [95% CI] and panel specificity of ≥98% [95% CI] for SNVs. FFPE samples performed comparably to FF samples (n=15 paired). Of 95 well-characterised genetic abnormalities in 33 clinical specimens and 13 cell lines (including SNVs, indels, amplifications, rearrangements and chromosome losses), 94 (98.9%) were detected by our approach. We have validated a robust and practical methodology to guide clinical management of children with solid tumours based on their molecular profiles. Our work demonstrates the value of targeted gene sequencing in the development of precision medicine strategies in paediatric oncology.
|Number of pages||15|
|Publication status||Published - 6 Dec 2017|